Fidaxomicin

CAS 873857-62-6 5 current recordsSmall Molecule

Who holds supplier records for Fidaxomicin? 5 organisations hold a current record for Fidaxomicin: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: China (2), India (1) and Netherlands (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Fidaxomicin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/fidaxomicin

Reading the evidence

  • 5 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Fidaxomicin expires 28 Nov 2034. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (5)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Fidaxomicin. Country is the organisation's recorded country, not necessarily the manufacturing site.

China2India1Netherlands1Country not recorded for 1
Need Fidaxomicin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (7 listed products contain Fidaxomicin). The latest listed patent expires 28 Nov 2034. The latest listed exclusivity runs to 24 Jan 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Fidaxomicin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1255800).

Chemical identity

IUPAC name
[(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
Canonical SMILES
CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\C)\C)[C@@H](C)O)\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\C
InChIKey
ZVGNESXIJDCBKN-UUEYKCAUSA-N
Synonyms
Dificid, Dificlir, Fidaxomicin, Fidaxomicina, Fidaxomicine, OPT-80, PAR-101, Tiacumicin B, Lipiarmicin, Difimicin, Lipiarmycin A3, OPT 80

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Macrolide Antibacterial
Chemical structure
Macrolides

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Fidaxomicin?

5 organisations hold an active US FDA Type II Drug Master File or a CEP for Fidaxomicin: BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD (China), CONCORD BIOTECH LTD (India), HUBEI HONCH PHARMACEUTICAL CO LTD, NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD (China) and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Fidaxomicin Drug Master Files are active?

BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD (DMF 28803, 38815), CONCORD BIOTECH LTD (DMF 44455), HUBEI HONCH PHARMACEUTICAL CO LTD (DMF 42162), NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD (DMF 29374) and TAPI NL BV (DMF 43653). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Fidaxomicin?

Yes. The latest patent listed for an approved US product containing Fidaxomicin expires 28 Nov 2034, across 7 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Fidaxomicin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Fidaxomicin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.